The US Food and Drug Administration (FDA) just green-lighted Filament Health Corporation, a clinical-stage company in the natural psychedelic medicine development business, to do a study on the effects of certain psychedelic drugs. Filament has already created around 70 strains of psychedelic mushrooms to be used for research, and they were able to raise a cool $2.5 million to continue studying the use of psychedelics through stabilized formulas. These would offer patients the benefits of better bioavailability, consistency, and a quicker onset as well as a reduction in side effects.
Here's this week's Good Grades review of Eaton Botanicals new flavors: Gal Pal and Daily…
Here’s how you can support New York’s new legal cannabis dispensaries. The post New York’s…
The regulatory crackdown on intoxicating hemp products across multiple states underscores the complex interplay between…
During our conversation, my friend posited that cannabis could be a detriment to one's spiritual…
Florida Governor Ron DeSantis recently vetoed a bill that would have severely restricted the sale…
However, a glimmer of hope has emerged from an unlikely source: cannabis. Some individuals with…